

Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (amended) A method for treating an angiogenesis-dependent disease in a mammal in need thereof comprising administering to the mammal an EMMPRIN antagonist monoclonal antibody or fragment thereof in an amount effective to inhibit angiogenesis in said mammal, wherein the angiogenesis-dependent disease is cancer.
2. (canceled)
3. (amended) The method according to claim [2] 1, in which the antibody fragment is an Fab, Fab', or F(ab')₂ fragment ~~or derivative thereof~~.
4. (amended) The method according to claim [2] 1, in which the monoclonal antibody is administered intravenously.
5. (amended) The method according to claim [2] 1, in which the monoclonal antibody is administered in the amount of from 0.05 mg/kg to 12.0 mg/kg body weight.
6. (amended). The method according to claim [2] 1, in which the monoclonal antibody is administered in a bolus dose followed by an infusion of said antibody.
7. (previously submitted) The method according to claim 1, in which the mammal is a human patient.
8. (canceled)
9. (amended) The method according to claim 1, wherein the angiogenesis-dependent diseases is a disease selected from the group consisting of angioma[,] and angiofibroma, ~~diabetic retinopathy, premature infant's retinopathy, neovascular glaucoma, corneal disease induced by angiogenesis, involutinal macula, macular degeneration, pterygium, retinal degeneration, retrolental fibroplasias, granular conjunctivitis, psoriasis, telangiectasis, pyogenic granuloma, seborrheic dermatitis, aene and arthritis.~~
10. (canceled)
11. (canceled)
12. (canceled)
13. (amended) A method for inhibiting tumor growth in a mammal in need thereof comprising administering to the mammal an EMMPRIN antagonist monoclonal antibody or fragment thereof in an amount effective to inhibit angiogenesis of the vasculature supporting the growth of said tumor.

14. (amended) A method for ~~preventing~~ treating tumor growth in a mammal in need thereof comprising administering to the mammal an EMMPRIN monoclonal antibody or fragment thereof in an amount effective to inhibit angiogenesis of the vasculature supporting the growth of said tumor.
15. (amended) A method for ~~preventing~~ treating metastases in a mammal in need thereof comprising administering to the mammal an EMMPRIN antagonist in an amount effective ~~prevent~~ treat metastases in said mammal.
16. (amended) A method of any of claims 1, [2,] ~~or 13, 14, or 15~~ wherein the EMMPRIN ~~antagonist~~ monoclonal antibody or fragment thereof is administered in combination with a second anti-angiogenic agent.
17. (previously submitted). A method of claim 16 where the second anti-angiogenic agent is a Mab capable of specifically binding the adhesion molecules containing alphaV.
18. (amended) The method according to claim [2] 1 wherein the monoclonal antibody competes for binding to human EMMPRIN with the monoclonal antibody CD147-RDI/clone UM-8D6.